Aethlon Medical Profit Margin 2010-2023 | AEMD

Current and historical gross margin, operating margin and net profit margin for Aethlon Medical (AEMD) over the last 10 years. Profit margin can be defined as the percentage of revenue that a company retains as income after the deduction of expenses. Aethlon Medical net profit margin as of December 31, 2023 is 0%.
Aethlon Medical Annual Profit Margins
Aethlon Medical Quarterly Profit Margins
Sector Industry Market Cap Revenue
Medical Medical - Health Maintenance Organizations $0.001B $0.001B
Aethlon Medical, Inc. is a development stage medical device company focused on expanding the applications of our Hemopurifier (R) platform technology, which is designed to rapidly reduce the presence of infectious viruses and other toxins from human blood. In this regard, its core focus is the development of therapeutic devices that treat acute viral conditions, chronic viral diseases and pathogens targeted as potential biological warfare agents. The Hemopurifier(R) combines the established scientific principles of affinity chromatography and hemodialysis as a means to mimic the immune system's response of clearing viruses and toxins from the blood before cell and organ infection can occur. The Hemopurifier(R) cannot cure viral conditions but can prevent virus and toxins from infecting unaffected tissues and cells. The company has completed pre-clinical blood testing of the Hemopurifier(R) to treat HIV and Hepatitis-C, and have completed human safety trials on Hepatitis-C infected patients in India.
Stock Name Country Market Cap PE Ratio
UnitedHealth Group (UNH) United States $481.868B 20.32
Cigna Group (CI) United States $95.557B 12.86
Humana (HUM) United States $42.854B 14.92
Centene (CNC) United States $41.839B 11.51
Molina Healthcare (MOH) United States $20.060B 16.45
Select Medical Holdings (SEM) United States $4.452B 15.56
Joint (JYNT) United States $0.245B 233.57